Cargando…
Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands
Severe infection of infants with respiratory syncytial virus (RSV) is a leading cause of morbidity in the developed world and mortality in the developing world. Prophylaxis using palivizumab in infants at risk for severe RSV disease reduces the rate of hospitalisation in this population of children....
Autores principales: | Whelan, Barbara, Musters, Elles, Murray, Amanda, Moore, Eilish, Lievaart, Lenie, Visser, Sjoerd, Toxopeus, Esther, van Veen, Annemarie, Notario, Gerard, Campbell, Fiona J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754330/ https://www.ncbi.nlm.nih.gov/pubmed/26924927 http://dx.doi.org/10.1007/s40267-015-0275-0 |
Ejemplares similares
-
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015) -
Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2023) -
Anticonvulsant drugs in migraine prophylaxis
por: Frediani, Fabio, et al.
Publicado: (2001) -
Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008) -
Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland
por: Linnane, Barry, et al.
Publicado: (2015)